The Latest Breaking News from Novo Nordisk

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Shares in Novo Nordisk were down 1.1% after the study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve